valproic acid has been researched along with antipyrine in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (40.00) | 18.7374 |
| 1990's | 3 (15.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 4 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jolivette, LJ; Ward, KW | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Hedges, A; Makki, KA; Monks, A; Oxley, J; Richens, A | 1 |
| Bachmann, KA; Forney, RB; Jauregui, L; Martin, M; Nunlee, M; Schwartz, J | 1 |
| Büchsel, R; Kohl, D; Kreiten, K; Matern, S; Wietholtz, H; Zysset, T | 1 |
| Bachmann, KA; Jahn, D; Schwartz, J; Yang, C | 2 |
| Hanano, M; Iga, T; Sawada, Y; Sugiyama, Y | 1 |
| Hedges, A; Makki, KA; Perucca, E; Richens, A; Ruprah, M; Wilson, JF | 1 |
| Laidlaw, J; Makki, K; Monks, A; Oxley, J; Richens, A | 1 |
| Chiba, K; Ishizaki, T; Nakazawa, Y; Tabuchi, T; Wagatsuma, T | 1 |
| Bachmann, KA; Jauregui, L | 1 |
| Ackley, DC; Yokel, RA | 1 |
| Alev, B; Emekli-Alturfan, E; Koc-Ozturk, L; Oktay, S; Tunali, S; Tunali-Akbay, T; Yanardag, R; Yarat, A | 1 |
| Alev, B; Emekli-Alturfan, E; Oktay, S; Ozturk, LK; Tunali, S; Tunali-Akbay, T; Yanardag, R; Yarat, A | 1 |
1 review(s) available for valproic acid and antipyrine
| Article | Year |
|---|---|
Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats.
Topics: Animals; Antipyrine; Barbiturates; Biological Availability; Chlorpromazine; Diazepam; Drug Evaluation; Female; Half-Life; Humans; Kinetics; Male; Metabolic Clearance Rate; Pentazocine; Pharmaceutical Preparations; Phenylbutazone; Phenytoin; Propranolol; Quinidine; Rats; Species Specificity; Tissue Distribution; Tolbutamide; Valproic Acid; Warfarin | 1985 |
1 trial(s) available for valproic acid and antipyrine
| Article | Year |
|---|---|
Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo.
Topics: Administration, Oral; Adult; Antipyrine; Aryl Hydrocarbon Hydroxylases; Carbamazepine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Ethosuximide; Humans; Liver; Lorazepam; Male; Oxidoreductases, N-Demethylating; Phenobarbital; Phenytoin; Quinidine; Rifampin; Smoking; Theophylline; Valproic Acid | 1993 |
18 other study(ies) available for valproic acid and antipyrine
| Article | Year |
|---|---|
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Lack of hepatic enzyme inducing effect of sodium valproate.
Topics: Adult; Antipyrine; Enzyme Induction; Epilepsy; Female; Glucaric Acid; Half-Life; Humans; Liver; Male; Middle Aged; Valproic Acid | 1979 |
The use of single sample clearance estimates to probe hepatic drug metabolism: handprinting the influence of cigarette smoking on human hepatic drug metabolism.
Topics: Antipyrine; Carbamazepine; Glucuronosyltransferase; Humans; Liver; Lorazepam; Male; Metabolic Clearance Rate; Microbodies; Microsomes, Liver; Mixed Function Oxygenases; Oxidoreductases; Pharmaceutical Preparations; Polycyclic Compounds; Quinidine; Smoking; Theophylline; Valproic Acid | 1990 |
Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism.
Topics: Adolescent; Adult; Aged; Antipyrine; Caffeine; Carbamazepine; Cytochrome P-450 Enzyme System; Enzyme Induction; Epilepsy; Female; Half-Life; Humans; Hydrocortisone; Male; Middle Aged; Phenytoin; Valproic Acid | 1989 |
The use of single sample clearance estimates to probe hepatic drug metabolism in rats. I.
Topics: Animals; Antipyrine; Liver; Male; Metabolic Clearance Rate; Mixed Function Oxygenases; Models, Biological; Pharmaceutical Preparations; Phenytoin; Rats; Rats, Inbred Strains; Theophylline; Valproic Acid; Warfarin | 1988 |
The use of single sample clearance estimates to probe hepatic drug metabolism in rats. II.
Topics: Animals; Antipyrine; Benzoflavones; beta-Naphthoflavone; Clofibrate; Drug Interactions; Liver; Male; Metabolic Clearance Rate; Pharmaceutical Preparations; Phenobarbital; Rats; Rats, Inbred Strains; Safrole; Theophylline; Valproic Acid; Warfarin | 1988 |
A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients.
Topics: Anticonvulsants; Antipyrine; Carbamazepine; Enzyme Induction; Epilepsy; Female; Glucaric Acid; Half-Life; Humans; Immunoenzyme Techniques; Male; Microsomes, Liver; Phenobarbital; Phenytoin; Primidone; Valproic Acid | 1984 |
Effects of sodium valproate on the serum protein binding of phenytoin, and on liver enzyme activity.
Topics: Antipyrine; Aspartate Aminotransferases; Blood Proteins; Glucaric Acid; Half-Life; Humans; Liver; Phenytoin; Protein Binding; Time Factors; Valproic Acid | 1980 |
Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy.
Topics: Adult; Anticonvulsants; Antipyrine; Delivery, Obstetric; Dose-Response Relationship, Drug; Epilepsy; Female; Half-Life; Humans; Infant, Newborn; Metabolic Clearance Rate; Phenobarbital; Phenytoin; Postpartum Period; Pregnancy; Pregnancy Complications; Time Factors; Valproic Acid | 1982 |
Aluminum citrate is transported from brain into blood via the monocarboxylic acid transporter located at the blood-brain barrier.
Topics: 2,4-Dinitrophenol; Aluminum; Animals; Antipyrine; Biological Transport, Active; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Citric Acid; Dialysis Solutions; Diffusion; Jugular Veins; Male; Microdialysis; Pyruvic Acid; Quaternary Ammonium Compounds; Rats; Rats, Sprague-Dawley; Valproic Acid | 1997 |
Edaravone ameliorates the adverse effects of valproic acid toxicity in small intestine.
Topics: Alkaline Phosphatase; Animals; Antipyrine; Edaravone; Female; Free Radical Scavengers; Glutathione; Glutathione Peroxidase; Glutathione Transferase; Intestine, Small; Malondialdehyde; N-Acetylneuraminic Acid; Peroxidase; Rats, Sprague-Dawley; Superoxide Dismutase; Thromboplastin; Valproic Acid | 2015 |
Effects of edaravone on cardiac damage in valproic acid induced toxicity.
Topics: Alkaline Phosphatase; Animals; Antipyrine; Catalase; Edaravone; Female; Glutathione; Glutathione Peroxidase; Glutathione Transferase; Lipid Peroxidation; Malondialdehyde; Myocardium; N-Acetylneuraminic Acid; Peroxidase; Rats; Sodium-Potassium-Exchanging ATPase; Superoxide Dismutase; Thromboplastin; Valproic Acid | 2015 |